ABOS Stock News & Analysis | Latest Updates

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences.

ABOS News

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Acumen Pharmaceuticals Q1 GAAP EPS $(0.48) Beats $(0.54) Estimate

Earnings Scheduled For May 13, 2025

A Preview Of Acumen Pharmaceuticals's Earnings

Acumen Pharmaceuticals Presented Extended Results From Its Validated Research-use Plasma pTau217 Assay To Screen Potential Participants In The Ongoing Phase 2 ALTITUDE-AD Trial Of Sabirnetug

UBS Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $4

Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday

Acumen Pharmaceuticals FY 2024 EPS $(1.71) Misses $(1.55) Estimate

Preview: Acumen Pharmaceuticals's Earnings

Acumen Pharmaceuticals Completes Enrollment In ALTITUDE-AD Phase 2 Clinical Trial Of ACU193 In Early Alzheimer's Disease, Plans To Report Topline Results, Including Efficacy And Safety Data, In Late 2026

Acumen Pharmaceuticals Announces Topline Results From Phase 1 Study Of Subcutaneous Formulation Of Sabirnetug In Healthy Volunteers; Weekly Subcutaneous Administration Of Sabirnetug Was Well-Tolerated In The Phase 1 Study

Acumen Pharmaceuticals Announces Upcoming Scientific Presentations On Alzheimer's Therapeutics At AD/PD In Vienna And AAN Annual Meeting In San Diego April 2025

Acumen Pharmaceuticals Announced That The Journal Of Prevention Of Alzheimer's Disease Published The Results Of The Phase 1 INTERCEPT-AD Trial Demonstrating That Sabirnetug (ACU 193) Was Generally Well-tolerated With Dose- And Exposure-dependent Target En

Acumen Pharmaceuticals Presented Encouraging Results For Phase 2 Of Its Clinical Trail For Alzheimer Screening Drug Sabirnetug

FDA And NIH Launch Public-Private Partnership For Rare Neurodegenerative Diseases